R

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Director, Medical Affairs - PDAC

Biology & BiotechConfirmed live in the last 24 hours
Full-timeRemote in USA

About the Job

Requirements

  • An advanced clinical or scientific degree such as PharmD, PhD, MD, DO, or equivalent is required.
  • At least 10 years of relevant experience in Medical Affairs within biotechnology or the pharmaceutical industry and/or prior clinical oncology practice is required.
  • A strong scientific background in oncology, meaningful experience in gastrointestinal cancers, and preferably direct PDAC experience are required.
  • Demonstrated ability to analyze, synthesize, and communicate complex clinical and scientific information to internal and external audiences is required.
  • Hands-on experience across core Medical Affairs activities, including medical strategy, field medical partnership, medical communications, medical information, evidence generation, publications, congress planning, advisory boards, and internal training is required.
  • Experience working effectively with cross-functional partners, including Clinical Development, HEOR/RWE, Biomarkers/Diagnostics, Commercial, Market Access, Regulatory, Safety, Legal, and Compliance, is required.
  • Excellent written, verbal, and presentation skills, including the ability to communicate a clear scientific point of view while maintaining appropriate medical balance, are required.
  • The ability to manage multiple priorities and stakeholders in a dynamic, evolving environment is required.
  • The ability to travel for internal meetings, external expert engagements, and medical congresses as required is required.

Responsibilities

  • Contribute to the development and execution of the US Medical Affairs strategy and annual medical plan for PDAC, including launch readiness, launch execution, and lifecycle planning.
  • Translate US-specific evidence gaps, treatment patterns, stakeholder needs, and field insights into clear medical objectives and executable tactics.
  • Lead or support scientific engagement with US external experts through advisory boards, investigator interactions, congress activities, and peer-to-peer scientific exchange.
  • Partner with US Field Medical to develop scientific priorities, insight-generation plans, training, and resources that support high-quality scientific exchange.
  • Synthesize insights from external experts, field teams, advisory boards, and other medical activities and communicate implications to internal stakeholders.
  • Serve as the PDAC medical content expert on US cross-functional teams and provide scientifically balanced medical input into strategic discussions and decisions.
  • Partner with HEOR/RWE, Clinical Development, and Biomarker/Companion Diagnostics teams on evidence-generation priorities addressing US clinical practice, patient identification, biomarker testing, treatment sequencing, safety management, and patient outcomes.
  • Coordinate gap assessments and contribute to publication, congress, medical communications, and evidence-generation plans aligned with the US medical strategy.
  • Support the development and review of scientific materials, medical education content, medical information response documents, abstracts, manuscripts, and data-disclosure materials.
  • Provide medical leadership for US congress planning, scientific symposia, advisory boards, and other medical activities, ensuring consistency, scientific accuracy, and compliance.
  • Partner with Patient Advocacy and Grants teams to incorporate the patient and caregiver perspective and help identify appropriate independent medical education priorities.
  • Collaborate with Safety and Clinical teams to support education and scientific exchange related to adverse-event recognition and management in PDAC.
  • Ensure all activities are conducted in accordance with applicable legal, regulatory, and compliance requirements.

Desired Qualifications

  • Established relationships with US PDAC experts, investigators, advocacy organizations, and multidisciplinary care stakeholders.
  • Experience supporting oncology product launch readiness, launch execution, or post-launch medical strategy in the United States.
  • Experience in precision oncology, RAS biology, biomarker testing, companion diagnostics, or targeted therapy development.
  • Understanding of the US PDAC care pathway, including community and academic treatment settings, patient referral patterns, molecular testing, treatment sequencing, and key evidence gaps.
  • Experience supporting clinical-trial strategy or execution, including protocol review, site and investigator engagement, enrollment support, and interpretation of clinical data.

About the Company

Revolution Medicines

Clinical-stage oncology company developing RAS inhibitors

Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Redwood City, CA
Founded
2014

Recently Posted Jobs

Explore more opportunities at Revolution Medicines

See more jobs